Many integrin adhesion receptors bind ligands containing the Arg-Gly-Asp (RGD) peptide motif. Most integrins exhibit considerable specificity for particular ligands and can distinguish among the many conformations of RGD. In this study we identify the domain of the integrin ␤ subunit involved in determining ligand binding specificity. Chimeras of ␤3 and ␤5, the most homologous integrin ␤ subunits, were expressed with ␣v on the surface of human 293 cells. The ligand binding phenotype of each chimera was assessed using the ligands Fab-9 and fibrinogen, both of which have a binding preference for ␣v␤3. The results of the study show that when exons C and D of the ␤3 subunit (residues 95-233) are substituted into ␤5, the chimera gained the ability to bind Fab-9 with an affinity close to that of wild-type ␣v␤3. This chimera was able to mediate cell adhesion to fibrinogen. Furthermore, the swap of only a 39-residue segment of this larger domain, ␤3 residues 164 -202, into the backbone of ␤5 enabled the chimeric integrin to bind soluble Fab-9. This small domain is highly divergent among the integrin ␤ subunits, suggesting that it may play a role in determining ligand selection by all integrins.
Integrins are transmembrane ␣␤ heterodimers that are responsible for most of the physical contacts between cells and the extracellular matrix. Integrins are involved in a number of tissue remodeling events including embryogenesis, angiogenesis, wound repair, and bone resorption (1) (2) (3) (4) (5) . Integrins are also causally linked to pathological conditions such as tumor progression, thrombosis, inflammation, and osteoporosis (6 -8) . The integrin protein family contains 13 ␣ and 9 ␤ subunits. These subunits can cross-pair to form heterodimers with different expression patterns and distinct ligand binding profiles (9, 10) . Each integrin binds to only a limited series of ligands, ensuring that cell adhesion and migration are precisely regulated. Such precision is key to tissue remodeling.
Based on their ligand recognition specificity, integrins can be divided into two broad sub-families. About one-half of the integrins bind to ligands that lack any consensus binding motif.
The remaining integrins bind to the RGD 1 consensus sequence. Importantly though, even the integrins that bind to RGD display a great deal of specificity for matrix ligands (11, 12) . Some of this specificity is determined by contacts that are ancillary to the RGD sequence (13, 14) , but much of the specificity is determined by the shape of the RGD motif and the residues in its immediate vicinity. Thus, to understand the structural basis of matrix selection, it is important to understand how integrins distinguish the many conformations of RGD.
The goal of the present study was to identify domain(s) within the integrin ␤ subunit that confer ligand binding specificity. As a model system, we compared the ligand binding domains of the two most homologous integrins, ␣v␤3 and ␣v␤5. The ␤3 and ␤5 subunits have 56% identity at the amino acid level (15, 16) . Although both ␣v␤3 and ␣v␤5 recognize the RGD motif, the ␣v␤3 integrin binds to at least six more ligands than ␣v␤5, indicating that ␣v␤3 has a more relaxed ligand binding specificity (17) . This difference in the way the two integrins bind to ligand may ultimately be related to their distinct biological functions. For example, while both ␣v␤3 and ␣v␤5 can mediate cell adhesion, only ␣v␤3 mediates cell spreading and migration in the absence of an external stimulus (18, 19) .
In the present investigation, we constructed a series of chimeras between ␤3 and ␤5 and assessed the ability of the chimeric integrins to bind to two ligands that exhibit significant binding preference for ␣v␤3 over ␣v␤5. One ligand, Fab-9, is an engineered Fab that contains an RGD sequence within the heavy chain complementarity determining region 3. Fab-9 was selected from a phage display library for the ability to bind the ␤3-integrins with high affinity (20) . In fact, this ligand exhibits greater than 1000-fold higher affinity for ␣v␤3 than for ␣v␤5 (20) . Another ligand, fibrinogen, is a protein involved in blood clotting and is thought to be a physiologic ligand for ␣v␤3 on endothelial cells (21, 22) . Prior study has shown that it fails to bind to ␣v␤5 (17) . Unlike Fab-9, fibrinogen contains multiple integrin-binding sites: two RGD motifs and an additional adhesive domain in the carboxyl terminus of its ␥ chain (23, 24) . Analysis of the ␤3/␤5 chimeras shows that exons C and D of the ␤3 subunit are key to determining the binding specificity for Fab-9 and fibrinogen. However, within this larger domain, a small region of only 39 amino acid residues has a significant impact on ligand selection. An alignment of this small domain in all integrin ␤ subunits shows it to be highly divergent. Structural algorithms also predict the region to be conformationally flexible. This is the first identification of a domain within the integrin ␤ subunit involved in ligand selection. In conjunction with our prior studies that map a region of the ␣ subunit that determines ligand binding specificity (25) , these results provide a structural basis for matrix selection by integrins.
EXPERIMENTAL PROCEDURES
Antibodies and Synthetic Peptides-Monoclonal antibody L230 (anti␣v) was purified from the culture supernatant of the hybridoma obtained from ATCC. The anti-␣v␤3 mAb LM609 was purchased from Chemicon. The mAb P112-4C1 that is specific for the ␣v␤3 complex was generated by conventional procedures at Searle/Monsanto. This antibody is specific for the complex between ␣v and ␤3 and blocks the integrin's ligand binding function. 2 The mAb RUU-PL7F12, which recognizes the ␤3 subunit, and mAb P1F6 (anti-␣v␤5) were purchased from Becton Dickinson. The mAb P3G2 (against ␣v␤5) was provided by Dr. David Cheresh (Scripps Research Institute). The polyclonal antibody directed against the ␤5 cytoplasmic tail was a kind gift from Dr. Lou Reichardt. Fab-9 is specific for the ␣v␤3 integrin ligand binding site. The characterization of this antibody has been previously described (20, 26) . Goat anti-human F(abЈ) 2 IgG was obtained from Pierce. Nonspecific mouse IgG was purchased from Calbiochem. Synthetic peptides with sequences GRGDSP and SPGDRG were synthesized by Coast Scientific.
Construction of Chimeras between Integrin ␤3 and ␤5-Wild-type ␤3 and ␤5 cDNA were cloned using PCR and verified by sequencing. Chimeras between ␤3 and ␤5 were designed based on the genomic sequence of ␤3, of which the exon junctions (labeled A-N) have been delineated (27) . As ␤5 is highly homologous to ␤3 in amino acid sequence, we designed the chimeras based on their sequence homology and placed the junctions of each chimera at or near the exon boundaries. Chimeras were constructed by PCR using ␤3/␤5 hybrid primers and primers that encompassed an endogenous restriction site. The resultant hybrid cDNA, consisting of ␤3 and ␤5 sequence flanked by restriction sites, was then cloned into the cDNA for ␤5 at endogenous restriction sites to complete the full-length integrin subunit. ␤3/␤5 hybrid primers (listed 5Ј to 3Ј) used to construct the junctions (/) of the chimeric integrin ␤ subunits were as follows: ␤3-(A-B)/␤5, GGTCTT-GTCACC/TGGCCGGAGCCGGAGTGCAATCCT and CGGCTCCGGC-CA/GGTGACAAGACCACCTTC; ␤3-(A-D)/␤5, ACAGTCTGTGAT/GA-GAAGATTGGCTGGCGAAAGGAT and GCCAATCTTCTC/ATCACAG-ACTGTAGCCTGCATGAT; ␤3-(C-D)/␤5, CTTCGAATCATC/GGGCCG-GAGGTTCACGGCAATCTC; ␤3-(A-J)/␤5, ACCTTTAAGAAA/GATTG-CGTCGAGTGCCCGCTGCTC and CTCGACGCAATC/TTTCTTAAAG-GTGCAGGCATCTGG; ␤3-(A-L)/␤5, AAGTCCATCCTG/SCCGTCCT-CAGGGAGCCAGAGTGT and CCTGAGGACGGT/CAGGATGGACTT-TCCACTAGAATC. To facilitate the cloning of the chimera containing ␤3 residues 164 -202, a silent EcoRV restriction site was introduced into ␤5 by mutagenesis. The point mutation at residue 587 (underlined) was made using the primer GTTGATAAGGATATCTCTCCTTTCTCC and the Chameleon Double-Stranded, Site-Directed Mutagenesis Kit (Stratagene). Hybrid primers were then used to generate the ␤3/␤5 junctions by PCR as follows: GATATCTCT/CCATACATGTATATCTCC and GGTGACCCGCTTC/AATGAGGAAGTTCGGAAACAGAGG. The chimera ␤3-(C-D)/␤5 was made by subcloning the amino-terminal ␤5 end into the cDNA encoding ␤3-(A-D)/␤5. The chimera ␤3-(A-I)/␤5 was made by replacing the amino-terminal fragment of ␤5 with ␤3 at the endogenous NcoI restriction site that is located at the end of exon I in both ␤3 and ␤5. The nucleotide sequence of each chimera was confirmed by dideoxy sequencing.
Cell Lines and FACS Analysis-Human embryonic kidney 293 cells obtained from ATCC were maintained in Dulbecco's modified Eagle's medium (Irvine Scientific) supplemented with 10% fetal calf serum (Irvine Scientific). The 293 cells contain ␣v and express no detectable ␣v␤3. The 293 cells express trace levels of ␣v␤5 (28) . Chimeric cDNAs consisting of human ␤3 and ␤5 cDNA were cloned into the expression vector pcDNA3 (Invitrogen) and transfected into 293 cells using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate transfection reagent (Boehringer Mannheim). Following selection in 500 g/ml geneticin (Life Technologies, Inc.) for 3 weeks, the cells were selected by FACS to obtain the top 5% of the expressing cells. These were chosen by sorting with antibodies against ␣v␤3 (P112-4C1) or anti-␣v␤5 (P1F6). Cells expanded from the sorted population were continuously monitored by FACS analysis for high expression of transfected integrin throughout the duration of the study. (29) .
The affinity of the chimeric integrins for Fab-9 was measured using cell surface binding studies essentially as described (28) . Briefly, cells (3 ϫ 10 6 /ml) in suspension were incubated with increasing concentrations of 125 I-Fab-9 at 14°C for 70 min. Nonspecific binding was measured by including 5 mM EDTA in the reaction mixture. Previous studies in this laboratory have shown that competition with an excess of unlabeled Fab-9 yields nearly identical values for nonspecific binding as does inclusion of EDTA. Following incubation, free 125 I-Fab-9 was separated from cell-bound ligand by centrifugation through 20% sucrose, 50 mM Tris-buffered saline, pH 7.4, at 14,000 rpm for 3 min in disposable microcentrifuge tubes (Fisher). The bottoms of the tubes containing the cell pellets were cut off and counted in a gamma counter. All data represent the average of triplicate measurements. All assays were repeated at least twice yielding nearly identical results. The affinity of the chimeric integrin for Fab-9 was calculated by Scatchard analysis (30) .
Immunoprecipitations-Immunoprecipitations used to assess the expression of chimeras on the surface of kidney 293 cells were performed as described previously except that 75 mM octylglucoside was used as the sole detergent (31) . A modified protocol was used to measure the binding of Fab-9 to the chimeras. Cells expressing chimeric integrin were labeled with 125 I using the lactoperoxidase method (32) . Cells were lysed in Lysis Buffer (75 mM octylglucoside (Calbiochem), 25 mM Tris, pH 7.7, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM MgCl 2 , and 0.05 mM MnCl 2 ). Cell lysates were precleared with Pansorbin (Calbiochem) and then lipid was removed using Seroclear (Calbiochem). Lysates were immunoprecipitated with P112-4C1 (anti-␣v␤3 mAb) for 18 h at 4°C. Chimeric integrins were eluted from the P112-4C1-linked Affi-Gel (Bio-Rad) with Elution Buffer (50 mM octylglucoside, 10 mM sodium acetate, pH 3.0). The eluted integrins were immediately neutralized by addition of 3 M Tris, pH 8.8. This material was dialyzed extensively against 50 mM octylglucoside, 100 mM NaCl, 25 mM Tris, pH 7.4, 0.5 mM MgCl 2 , and 0.05 mM MnCl 2 . The partially purified integrins were then immunoprecipitated with a concentration range of Fab-9 in Lysis Buffer containing 1 mg/ml bovine serum albumin. The complex between integrin and Fab-9 was precipitated by addition of protein A-agarose (Sigma) and a saturating amount of goat anti-human F(abЈ) 2 IgG. The protein bound to protein A-agarose was washed in Lysis Buffer and then with Tris-buffered saline containing 0.5 mM MgCl 2 and 0.05 mM MnCl 2 . Samples were analyzed on SDS-PAGE under non-reducing conditions. Chimeric integrins precipitated by Fab-9 were visualized by exposing the dried gel to a PhosphorImager (Bio-Rad). Each chimeric ␤ band was quantified as pixel density (PD) volume which was calculated as the mean PD multiplied by the area (mm 2 ) of the band. The apparent affinity of Fab-9 for the chimeric integrin was calculated as the concentration of Fab-9 that gave 50% of the maximal PD units at a saturating concentration of Fab-9. Quantitative immunoprecipitations were always done in parallel with cells expressing ␣v␤3.
Cell Adhesion Assay-The cell adhesion assay was conducted essentially as described (33) . Cells were harvested with 200 M EDTA/phosphate-buffered saline and resuspended in Hanks' balanced salt solution (Sigma) supplemented with 25 M MnCl 2 . 2 ϫ 10 5 cells were added to each well containing immobilized fibrinogen (20 nM) or vitronectin (10 nM). Cells were allowed to adhere for 45 min at 37°C. Nonadherent cells were removed by gentle washing, and the adherent cells were quantitated using a colorimetric assay for lysosomal acid phosphatase (34) .
RESULTS

Construction and Expression of Chimeras between ␤3
and ␤5-To identify domains of the integrin ␤ subunit involved in ligand binding specificity, we constructed chimeras between the ␤3 and ␤5 subunits. As some models suggest that domains of the ␤ subunit near the plasma membrane are linked to amino-terminal domains and contribute to ligand binding (35, 36) , we constructed several chimeras that contained relatively broad regions of ␤3 (Fig. 1) . Most chimeras were constructed based on the known exon junctions for ␤3 (27) . For example, ␤3-(A-L)/␤5 is a chimera containing ␤3 exons A through L (the entire extracellular domain) and the ␤5 transmembrane and cytoplasmic domains. The chimera ␤3-(C-D)/␤5 encompasses most of the regions of ␤3 thought to be part of the ligand binding site.
Expression of Chimeric Integrins on Kidney 293 Cells-The cDNAs encoding each chimera were used to transfect human embryonic kidney 293 cells. The stable expression of each chimera was monitored by FACS. For this analysis, we used monoclonal antibodies (mAb) P112-4C1 (anti-␣v␤3) and P1F6 (anti-␣v␤5). These antibodies are specific for the complex between ␣v and the respective ␤ subunit. Both antibodies also block the ligand binding function of integrin; hence, their ability to bind to the chimeras can be taken as evidence that the domain swaps do not grossly alter the fold of the hybrid integrins. Human 293 cells transfected with the control expression vector produced little endogenous ␣v␤3 or ␣v␤5 (Fig. 2A) . Cells transfected with cDNAs encoding wild-type ␤3 (Fig. 2B ) and wild-type ␤5 (Fig. 2E ) expressed substantial levels of each integrin. The chimera containing ␤3 exons A through I was detected with antibody P112-4C1 (Fig. 2C) . The chimera containing ␤3 exons A and B was detected with mAb P1F6 (Fig.  2D) . Results from FACS analysis of the remaining chimeras are summarized in Table I . Additional antibodies LM609 (anti␣v␤3) and P3G2 (anti-␣v␤5) reported identical expression levels as P112-4C1 and P1F6, respectively (Table I ). The anti-␤3 mAb RUU-PL7F12 did not bind to chimeras containing small regions of ␤3 within exons A-D. Three other chimeras that were constructed, ␤3-(A-E)/␤5, ␤3-(C-E)/␤5, and ␤3-(A-H)/␤5, were not expressed as a heterodimer with ␣v on the cell surface, even though reverse transcriptase-PCR analysis showed that mRNA for these ␤ subunits was produced by transfected cells.
Immunoprecipitation of Chimeric Integrins-Chimeras were analyzed by immunoprecipitation to confirm their association with ␣v and to quickly assess their ability to bind to Fab-9, a ligand specific for the ␤3-integrins. Cells were radiolabeled with 125 I and then precipitated with four different antibodies ( Under the conditions used to lyse the cells, the complex between the ␣ and ␤ subunit is not disrupted, so this assay also allowed us to quickly screen the chimeras for the ability to bind to Fab-9. Lane 4 of each panel in Fig. 3 shows an immunoprecipitation using Fab-9 at a concentration of 190 nM. This level of Fab-9 is known to be 19-fold above the K D of Fab-9 for wild-type ␣v␤3 (see Table I ). As expected, Fab-9 precipitated ␣v␤3 (B) but not ␣v␤5 (E). One chimera, ␤3-(A-B)/␤5 (C) failed to bind Fab-9, indicating that exons A and B of ␤3 are not sufficient to confer ligand binding specificity. In contrast, the chimeras containing ␤3 exons A-L, A-J, A-I, A-D (D), C-D, and ␤3 residues 164 -202 were all precipitated by Fab-9, indicating that each has ␤3-like binding specificity (not all data shown). The affinity of these chimeras for Fab-9 was subsequently studied in detail (see below).
The Chimera Containing Exons A and B of ␤3 Can Bind Vitronectin but Not Fab-9 -One chimera, ␤3-(A-B)/␤5, was recognized by the function-blocking antibodies P1F6 (Fig. 2 , Table  I ) and P3G2 (not shown), both of which are specific for the FIG. 1. The chimeric ␤3/␤5 subunits. Chimeras between the ␤3 and ␤5 integrin subunits were designed based on the exon junctions of ␤3 (27) . The name of each chimera is derived from the exons or amino acid residues of ␤3 that were substituted into ␤5. Regions corresponding to the RGD cross-linking sites (bars) (38, 40) and other ligand contact sites (asterisks) (42, 45) are noted above the figure. Table I. complex between ␣v and ␤5. ␤3-(A-B)/␤5 was also found to lack the ability to bind Fab-9 ( Fig. 3) , indicating that it does not have the ligand binding specificity of ␣v␤3. To confirm that ␤3-(A-B)/␤5 had ligand binding function, we measured its ability to bind soluble vitronectin. We have previously shown that soluble vitronectin has high affinity for ␣v␤5 but much less affinity for ␣v␤3 (28). The ␤3-(A-B)/␤5 chimera bound to 125 Ivitronectin with an affinity only 3.2-fold lower than that of wild-type ␣v␤5 (29 versus 9 nM, respectively) (Fig. 4) . The binding was almost completely abolished with antibody L230, which blocks ligand binding to all ␣v-integrins (37), and by RGD peptide (not shown). Because the ␤3-(A-B)/␤5 chimera was capable of binding to vitronectin, but incapable of binding to Fab-9, we conclude that exons A and B of the integrin ␤ subunit do not substantially contribute to ligand binding specificity. This conclusion is also supported by the inability of cells expressing this chimera to adhere to fibrinogen (see below).
Measuring the Affinity between Fab-9 and the Chimeras of ␤3 and ␤5-All of the chimeras except ␤3-(A-B)/␤5 indicated some ability to bind to Fab-9 using the immunoprecipitation assay at a saturating Fab-9 concentration (Fig. 3) . As a next step, we used a cell surface binding assay to measure the binding affinity of these chimeras for Fab-9. The binding of 125 I-Fab-9 to cells expressing the chimeras was measured at 14°C to prevent the internalization of ligand. The binding isotherms between 125 I-Fab-9 and cells expressing ␣v␤3 or ␤3-(A-I)/␤5 are shown in Fig. 5 as an example. The chimera containing exons A-I of ␤3 has an affinity for Fab-9 that is equivalent to that of wildtype ␣v␤3. Chimeras containing larger domains of ␤3 (exons A-J and A-L) also bound to Fab-9 with an affinity identical to wild type ␣v␤3 (Table II) . Based on these observations, it can be concluded that a swap of exons A-I in the ␤3 subunit is sufficient to change the integrin's ligand recognition specificity. As previously reported, Fab-9 failed to specifically bind to cells expressing wild-type ␣v␤5 (28) and also failed to bind the ␤3-(A-B)/␤5 chimera in this quantitative assay (data not shown). In conjunction with the data shown in Figs. 3 and 4 , which indicate that exons A and B are not involved in ligand selection, these findings suggest that the domain encompassing ␤3 exons C-I is important for determining complete ligand binding specificity.
Residues 164 -202 of ␤3 Are Sufficient to Confer Partial Ligand Binding Specificity-Because the cell surface binding assay resulted in high nonspecific binding at 125 I-Fab-9 concentrations above 30 nM, the affinity of Fab-9 for chimeras exhibiting a low affinity for Fab-9 could not be determined reliably with this assay. Consequently, a quantitative immunoprecipitation assay was used to measure the affinity of the chimeras ␤3-(A-D)/␤5, ␤3-(C-D)/␤5, and ␤3-(164 -202)/␤5 for Fab-9. Cells expressing each chimera were surface labeled with 125 INa and then lysed in octylglucoside. Each chimera was immunoprecipitated from the lysate with antibody P112-4C1 (against ␣v␤3), an antibody known to recognize each chimera in FACS (Table I) . Chimeric integrins were then eluted from this antibody and re-precipitated with a concentration range of Fab-9. Immunoprecipitated proteins were resolved by SDS-PAGE, and the amount of each chimera bound to Fab-9 was quantified using a PhosphorImager (Fig. 6A) . To obtain a binding isotherm, the pixel density volume of the band corresponding to the ␤ subunit was plotted against the concentration of Fab-9 used in the immunoprecipitation. Plots of pixel density volumes obtained from the ␣ subunit gave nearly identical results. Examples of binding isotherms from two separate experiments are shown in Fig. 6B . In this assay, the affinity between ␣v␤3 and Fab-9 is 0.5 nM. This value is 10-fold higher than that measured in the cell surface binding assay (Fig. 5) but nearly equivalent to the value we have previously reported for ␣v␤3 purified from placenta (20) . Both the purified integrin (38) and the integrin examined in the quantitative immunoprecipitation assay are subject to elution from antibody with low pH. Therefore, we suspect that treatment with low pH enhances the affinity of the integrin for ligand. Nevertheless, in this study the affinity of the chimeric integrins was always compared with ␣v␤3 measured in the same assay (Table II) , so the relative affinities are directly comparable. 
a FACS reactivity is quantitated by subtracting the mean fluorescence intensity of the nonspecific mouse IgG control from the mean fluorescence intensity of the anti-integrin mAb: Ϫ, 1-5 (not different than nonspecific mouse IgG); ϩ/Ϫ, 5-10; ϩ, 11-30; ϩϩ, 31-50; ϩϩϩ, greater than 50.
b Monoclonal antibody P3G2 (anti-␣v␤5) gave results identical to mAb P1F6 (not shown).
The affinity of Fab-9 for ␤3-(A-D)/␤5 and ␤3-(C-D)/␤5 was approximately 10-fold lower than for ␣v␤3 (Table II) . Thus, these domains contain nearly all of the binding contacts needed to obtain specificity for Fab-9. The chimera containing ␤3 residues 164 -202, a region chosen for a swap because it is contained within exons C-D and was predicted to be a highly flexible loop (28) , also bound to Fab-9. The affinity of ␤3-(164 -202)/␤5 for Fab-9 was 35-fold lower than that exhibited by ␣v␤3 but still significantly higher than that of ␣v␤5, which exhibits at least 1000-fold lower affinity for Fab-9. The results of all binding studies with Fab-9 are summarized in Table II .
Measuring the Ability of ␤3/␤5 Chimeras to Mediate Cell Adhesion to Fibrinogen-Cell adhesion assays were conducted to determine which chimeras could mediate adhesion to fibrinogen, a natural adhesive ligand that will bind ␣v␤3 but not ␣v␤5 (17) . In general, the ability of the chimeras to mediate adhesion to fibrinogen was similar to their ability to bind to Fab-9. As shown in Fig. 7 , cells expressing ␣v␤3, ␤3-(A-I)/␤5, and ␤3-(C-D)/␤5 could all adhere to immobilized fibrinogen. As predicted from the binding studies with Fab-9, cells expressing ␣v␤5 or ␤3-(A-B)/␤5 did not adhere to fibrinogen. Interestingly, cells expressing ␤3-(164 -202)/␤5 also failed to adhere to fibrinogen, even though this chimera could bind to Fab-9. All cell lines were able to adhere to immobilized vitronectin (Fig.  7) , indicating that the chimeric integrins were functional in adhesive capability. Adhesion to both fibrinogen and vitronectin was inhibited by inclusion of RGD peptide in the assay (data not shown).
DISCUSSION
The goal of this study was to identify the domains within the integrin ␤ subunit that have an impact on ligand binding specificity. This was achieved by examining the ligand binding phenotype of chimeras between the integrin ␤3 and ␤5 subunits. The major findings of this study are as follows: 1) the domain of the integrin ␤3 subunit involved in determining complete ligand binding specificity encompasses residues 95-537 (exons C-I); 2) chimeras containing smaller domains of ␤3 exhibited reduced affinity for ␤3-specific ligands (␤3 ϭ ␤3-(A-I)/␤5 Ͼ ␤3-(C-D)/␤5 Ͼ ␤3-(164 -202)/␤5). This stepwise loss in binding affinity suggests that optimal ligand binding specificity is achieved through the contact of ligand with several discontinuous domains of the ␤ subunit; 3) the replacement of a small region of the ␤5 subunit with the homologous region of ␤3 (residues 164 -202) is sufficient to alter the ligand binding phenotype of the integrin. This small domain is highly divergent among the integrin ␤ subunits, suggesting that it is likely to be a key structural element responsible for ligand selection by all integrins.
The results of this study should be interpreted in the context of the current understanding of how integrins bind their ligands. Several lines of evidence show that the integrin ligand I-vitronectin in suspension at 14°C with increasing amounts of unlabeled vitronectin (top panels). The mAb L230 was used in these binding studies to confirm that binding was mediated by ␣v-integrin. Antibody P3G2 is a function-blocking mAb against the ␣v␤5 complex and was applied as an antagonist to verify that binding was mediated by ␣v␤5 or ␤3(A-B)/␤5. The binding isotherms were converted to Scatchard plots (bottom panels) to obtain binding affinity. Each binding assay was performed at least twice yielding identical results.
binding pocket is comprised of amino acid residues on both the ␣ and ␤ subunits (39, 40) . Cross-linking studies localize the RGD ligand binding site on the ␤3 subunit to residues 61-203 in the context of ␣v␤3 (38) and residues 109 -171 in the context of ␣IIb␤3 (41) . Several other studies show that peptides derived from these regions of ␤3 exhibit some ability to bind ligand (41) (42) (43) (44) (45) . Collectively, these studies map the general location of the ligand binding site, but they fail to address the basis for ligand binding specificity. Here, we demonstrate that a small domain consisting of ␤3 residues 164 -202 is involved in ligand selection. We have previously analyzed the structure of this region with the PHD algorithm, and it is predicted to be a flexible loop (28) . An alignment of this region among known human integrin ␤ subunits is shown in Fig. 8 . The considerable homology among all integrin ␤ subunits of the areas flanking ␤3 residues 164 -202 has implications for the structure of the ligand binding pocket. First, the architecture of the site is probably defined by the stretches of amino acid residues that are highly homologous among all ␤ subunits. Second, the binding pocket appears to contain a metal binding site comprised of conserved liganding residues from noncontiguous domains (28, 46 -48) . Finally, the ligand binding site of each integrin ␤ subunit contains a domain corresponding to ␤3 residues 164 -202 which is highly divergent and which normally encompasses a disulfide-bonded loop of variable length. These data suggest that this domain may have a substantial impact on the ligand selection of all integrins. The association of such a divergent, flexible structure with integrin ligand binding specificity is reminiscent of other proteins in which highly variable loops determine ligand binding preference. For example, the complementarity determining regions of many IgG proteins, including antibodies and the T cell receptor, are the major determinants of immunologic recognition (49, 50) .
The findings presented here suggest that the ligand binding site of the ␤3-(164 -202)/␤5 chimera is quite similar to that of Whole cell binding Immunoprecipitation Table II ). Each binding assay was conducted three times, with similar results.
␤3 and unlike that of ␤5. How closely does the structure of ␤3-(164 -202)/␤5 mimic the structure of ␤3? This question can be addressed by converting the binding constants between Fab-9 and the integrins to theoretical free energy (⌬G 0 ). Using the affinity measurements shown in Table II and the equation (⌬G 0 ϭ Ϫ1364 log(1/K D )) (51), the difference in ⌬G 0 for Fab-9 binding to ␣v␤3 versus the ␤3-(164 -202)/␤5 integrin is only about Ϫ2 kcal/mol. The reported energies of a single hydrogen bond, hydrophobic interaction, or salt bridge are all between Ϫ1 and Ϫ4 kcal/mol (52) . Therefore, the difference in the way that ␣v␤3 and the ␤3-(164 -202)/␤5 integrin bind to Fab-9 can be theoretically equated to the loss of only one or two bonds.
Interestingly, the ␤3-(164 -202)/␤5 integrin bound to soluble Fab-9 but did not mediate cell adhesion to fibrinogen. Since the affinity of this chimera for Fab-9 is 35-fold lower than ␣v␤3, the simplest interpretation of these data is that the chimera simply lacks sufficient affinity for fibrinogen to mediate cell adhesion. However, these findings could also be interpreted differently because there are important distinctions in the way that Fab-9 and fibrinogen bind to ␣v␤3. Fab-9 contains an RGD in complementarity determining region 3 that has been optimized to bind the ␤3-integrins. This 9-residue loop is presumably the only contact within the antibody for integrin (53) . Fab-9 also binds to integrins in a reversible manner (26) . Although fibrin- ogen also binds to ␣v␤3 through an RGD motif, it binds irreversibly (54) . This irreversible binding is probably due to the formation of additional contacts between integrin and ligand. Therefore, it is possible that while the region encompassing ␤3 residues 164 -202 is capable of conferring binding to specific presentations of the RGD motif (such as that reported by Fab-9), it is not sufficient to make additional contacts essential for stable binding of fibrinogen. Such a difference may account for the inability of this chimera to promote cell adhesion. Importantly, the chimera that contained exons C and D, a somewhat larger region of ␤3, did support adhesion to fibrinogen. Therefore, all of the structural information required for fibrinogen binding is contained within these two exons.
Our study also provides information on the binding sites of four monoclonal antibodies that block integrin function. Antibodies P112-4C1 and LM609 are specific for the ␣v␤3 complex and block cell adhesion mediated by this integrin. Antibodies P1F6 and P3G2 bind the complex between ␣v␤5 and inhibit ␣v␤5-mediated cell adhesion. The smallest chimera examined, ␤3-(164 -202)/␤5, can bind to the ␣v␤3-specific antibodies and has lost the ability to bind the ␣v␤5-specific antibodies. This finding suggests that the domain corresponding to ␤3 residues 164 -202 may contain the epitope for many integrin complexspecific, function-blocking antibodies. Alternatively, this domain may contact the ␣v subunit and regulate the conformation of the epitope by modifying ␣v.
One current goal is to obtain the three-dimensional structure of the integrin ligand binding site. Unfortunately, this is not likely to be technically possible using full-length integrin subunits; it will have to be achieved with truncated forms of each subunit. Ideally a truncated integrin would contain all of the structural information required to confer ligand selection. In conjunction with our prior report showing that the first two cation binding sites of the ␣IIb subunit are necessary (in addition to the amino-terminal domain) for conferring ligand binding specificity (25) , the present study indicates that the minimal integrin domains necessary for achieving ligand binding specificity are ␣IIb residues 1-334 and ␤3 residues 164 -202. The feasibility of expressing truncated integrins was recently shown by McKay and colleagues (55) , who were able to express an integrin heterodimer consisting of ␣IIb residues 1-233 and ␤3 residues 111-318. Such truncated integrins may be ideal for structural analysis as they are likely to reveal the conformational differences that account for ligand selection.
FIG. 8.
Comparison of the amino acid sequence of ␤3 residues 164 -202 with other integrin ␤ subunits. The amino acid sequences of human integrin ␤ subunits ␤1-␤8 corresponding to ␤3 residues 114 -252 were aligned using ClustalW (56) . This domain contains 50 amino acids before and after the region of ␤3 164 -202. Amino acid residues that are identical among all 8 subunits are shaded. Positions containing conservative substitutions are boxed. The dashed lines above the sequences show the position of ␤3 164 -202. Asterisks mark the residues that have been identified as important for ligand and metal ion binding function of several integrins (28, 46 -48) . Cysteines 177 and 184 in the ␤3 subunit are known to form a disulfide bond (36) .
